AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
18.59
-0.28 (-1.48%)
Feb 21, 2025, 4:00 PM EST - Market closed
AnaptysBio Revenue
AnaptysBio had revenue of $30.02M in the quarter ending September 30, 2024, with 804.67% growth. This brings the company's revenue in the last twelve months to $57.17M, up 282.17% year-over-year. In the year 2023, AnaptysBio had annual revenue of $17.16M with 66.78% growth.
Revenue (ttm)
$57.17M
Revenue Growth
+282.17%
P/S Ratio
8.91
Revenue / Employee
$488,650
Employees
117
Market Cap
565.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ANAB News
- 10 days ago - Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months - GlobeNewsWire
- 10 days ago - Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 - GlobeNewsWire
- 19 days ago - Anaptys to Present at the Guggenheim SMID Cap Biotech Conference - GlobeNewsWire
- 19 days ago - Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist - GlobeNewsWire
- 6 weeks ago - Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data - Benzinga
- 2 months ago - AnaptysBio to abandon eczema drug development after mid-stage trial failure - Reuters
- 2 months ago - AnaptysBio abandons eczema drug development after mid-stage trial failure - Reuters